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Approximately 2 million new cancer cases are attributed to infectious agents each year worldwide.
Vaccines for the hepatitis B virus (HBV), a risk factor of hepatocellular cancer, and human papillomavirus
(HPV), a risk factor of cervical cancer, are considered major successes in clinical chemoprevention of
cancer. In Taiwan, the ﬁrst evidence of cancer prevention through vaccinations was provided by HBV
vaccination data in infants. The Taiwanese HBV vaccination program has since become a model immu-
nization schedule for newborns worldwide. Persistent infection with high-risk HPV is generally accepted
as prerequisite for cervical cancer diagnosis; however, cervical cancer is a rare complication of HPV
infections. This is due to the fact that such infections tend to be transient. The safety and efﬁcacy of both
available HPV quadrivalent vaccine and bivalent vaccine are not in doubt at the present time. Until a
human cytomegalovirus (CMV) vaccine becomes available, simple hygienic practices, such as hand
washing, can prevent CMV infection both before and during pregnancy. Each country should establish
her ofﬁcial guidelines regarding which vaccines should be used to treat various conditions, the target
population (i.e., universal or limited to a selected population), and the immunization schedules. After a
vaccine is recommended, decisions regarding reimbursement by the public health care fund are evalu-
ated. The guidelines become part of the immunization schedule, which is updated annually and pub-
lished in the ofﬁcial bulletin. In conclusion, both HBV and HPV vaccines are considered major successes in
the chemoprevention of cancer.
Copyright © 2015, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All
rights reserved.Introduction
Vaccines for the hepatitis B virus (HBV), a risk factor of hepa-
tocellular cancer, and human papillomavirus (HPV), a risk factor of
cervical cancer, are considered major successes in clinical chemo-
prevention of cancer. In Taiwan, the ﬁrst evidence of cancer pre-
vention through vaccinations was provided by HBV vaccination
data in infants. The Taiwanese HBV vaccination program has since
become a model immunization schedule for newborns worldwide.
The safety and efﬁcacy of both two available HPV vaccines (quad-
rivalent vaccine and bivalent vaccine) are not in doubt at the pre-
sent time. This review is to summarize the current conception of
immunization and vaccination for general obstetricians and gyne-
cologists, and women health care personnel.ang Tien General Hospital,
ity, Taiwan.
bstetrics & Gynecology. PublishedCase review
Worldwide, approximately 2 million new cancer cases are
attributed to infectious agents each year [1]. Protection against
infectious disease through prior asymptomatic infection is based
on the concept of variolation (inoculation with smallpox). In 1796,
upon recognizing that dairymaids infected with cowpox were
immune to smallpox, English physician Edward Jenner deliber-
ately infected 8-year-old James Phipps with cowpox. After
repeating the experiment on other children, including his own
son, Doctor Jenner concluded that vaccination provided immunity
to smallpox without the risks associated with variolation. Results
of the ﬁrst successful smallpox vaccination were published in
1798. New vaccination policies should include considerations of
safety, efﬁcacy, and cost-effectiveness. Guidelines for immuniza-
tion should consider the ages of subjects, the number of doses, as
well as dosing intervals, precautions, and contraindications of
vaccines [2].by Elsevier Taiwan LLC. All rights reserved.
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Vaccines for the hepatitis B virus (HBV), a risk factor of hepa-
tocellular cancer (HCC), and human papillomavirus (HPV), a risk
factor of cervical cancer, are considered major successes in clinical
chemoprevention of cancer. The ﬁrst randomized blind controlled
trial of hepatitis B immunoglobulin (HBIG) and hepatitis B vaccine
in Taipei was reported in 1983. In that study, the infants of mothers
carrying the e-antigen-positive hepatitis B surface antigen (HBsAg)
were given HBIG immediately after birth, followed by one of three
vaccination schedules. No difference in efﬁcacy was observed be-
tween the three schedules, and the combined efﬁcacy was 94% [3].
A total of 38 healthy infants received two 20 mg doses of the vaccine
through the intramuscular route with a 1-month interval between
doses. All developed antibodies to HBsAg (anti-HBs) following the
third dose at the age of 7 months. Furthermore, anti-HBs were
maintained at high levels after vaccinating infants who initially
possessed passive antibodies [4]. In another study conducted in
1983, a total of 100 healthy children received two doses of HBV
vaccine (10 mg, 20 mg, or 40 mg) at 1-month intervals, 90% of the
children still presented antibodies 12 months after vaccination [5].
Hepatitis B is a common infectionworldwide, and the severity of
the infection is related to the age of the affected individual. The
development of the hepatitis B vaccine is considered a major
achievement of modern medicine. Current hepatitis B vaccines are
extremely safe and provide an efﬁcacy rate < 90%. Nonetheless,
more than 2 billion individuals worldwide present serological ev-
idence of hepatitis B infection. Of these, 400 million are chronic
carriers, and between 0.5 and 1.2 million die annually from
cirrhosis and HCC [6].
By 2004, 18,779 people under the age of 30 years (including
neonates) had been administered the universal hepatitis B vacci-
nation in Taiwan. The seropositive rate for HBsAg was found to be
1.2% in these individuals. These results demonstrate that the uni-
versal HBV vaccination program provided protection for up to 20
years [7]. In a systematic review of hepatitis B immunization in
infants born to HBsAg-positive mothers, the results of 29 ran-
domized clinical trials (ﬁve of which are considered high-quality)
that compared vaccination to placebo/no intervention showed
that vaccinations reduced the occurrence of hepatitis B [relative
risk (RR) 0.28, 95% conﬁdence interval (CI)] 0.20 to 0.40, four trials.
In studies that compared the efﬁcacy of different vaccines, the
administration of vaccines and HBIG succeeded in reducing the
occurrence of hepatitis B (RR 0.54, 95% CI) 0.41 to 0.73, 10 trials [8].
Additionally, chronic HBV infection (HBsAg-positive) rates in the
general population < 20 years of age dropped considerably from
10e17% before the mass HBV vaccination program to 0.7e1.7% after
the program. The incidence of HCC among Taiwanese children 6e14
years old also fell from 0.52e0.54 to 0.13e0.20 per 100,000
(RR ¼ 0.25e0.36) [9]. Thus, in Taiwan, the ﬁrst evidence of cancer
prevention through vaccinations was provided by HBV vaccination
data in infants. The Taiwanese HBV vaccination program has since
become a model immunization schedule for newborns worldwide.
The concept of a cancer preventive vaccine can be extended to
other infectious agents and their related cancers [10].
For reference, the immunization schedule for routine vaccina-
tions in the U.S. is summarized below [11].
Vaccination of all children aged 0e18 years
Vaccinate all newborns with monovalent vaccine before
discharge from hospital. Give the second dose at 1e2 months and
the ﬁnal dose at 6e18 months. After the ﬁrst dose administered at
birth, the series may be completed using two doses of single-
antigen vaccine or as many as three doses of Comvax[Haemophilus b Conjugate Vaccine (Meningococcal Protein Con-
jugate) & Hepatitis B Vaccine (Recombinant)] (ages 2 months, 4
months, 12e15 months) or Pediarix [Diphtheria and Tetanus Tox-
oids and Acellular Pertussis Adsorbed, Hepatitis B (Recombinant)
and Inactivated Poliovirus Vaccine Combined] (ages 2 months, 4
months, 6 months). For cases in which the mother is HBsAg-
positive, the newborn is to be administered HBIG and the ﬁrst
dose within 12 hours of birth. The series should be complete by the
age of 6 months or, if using Comvax, by the age of 12e15 months.
For cases in which the HBsAg status of the mother is unknown, the
newborn should also be administered HBIG and the ﬁrst dose of
vaccine within 12 hours of birth. The same protocol should be
followed for cases of low birth weight (<2000 g). For cases of low
birth weight and an infant weighing  2000 g, whose mother is
subsequently found to be HBsAg-positive, the infant is to be
administeredHBIG as soon as possible/immediately (no later than 7
days following birth), followed by the hepatitis B immunization
schedule for infants born to HBsAg-positive mothers.
Catch-up vaccination
No vaccination series is to be restarted, regardless of how much
time has elapsed since the previous dose. Three-dose series can be
started at any age with the minimum interval between doses as
follows: 4 weeks between the ﬁrst and second doses, 8 weeks be-
tween the second and third doses, and at least 16 weeks between
the ﬁrst and third doses.
Special note:
Monovalent vaccine brands are interchangeable. For patients
aged 0e19 years, administer 0.5 mL of either Engerix-B or
Recombivax HB.
An alternate dosing schedule for unvaccinated adolescents aged
11e15 years is as follows: two doses Recombivax HB 1.0 mL (adult
formulation) spaced 4e6 months apart. (Engerix-B is not licensed
for a two-dose schedule.)
Preterm infants
Preterm infants weighing < 2000 g and born to HBsAg-negative
mothers should have their ﬁrst vaccine dose delayed until 1 month
after birth or at the time of hospital discharge. Preterm infants
weighing < 2000 g and born to HBsAg-positive mothers should
receive both HBIG (0.5 mL) and single-antigen hepatitis B vaccine
12 hours after birth, administered at various injection sites. The
initial dose of vaccine (birth dose) should not be counted as part of
the vaccine series, and three additional doses of the vaccine (for a
total of four doses) should be administered beginning when the
infant reaches 1 month of age. For cases in which the mother's
HBsAg status cannot be determined, preterm infants weighing <
2000 g should receive both HBIG (0.5 mL) and single-antigen
hepatitis B vaccine within 12 hours of birth. The birth dose
should not be counted as part of the vaccine series, and three
additional doses of vaccine (for a total of four doses) should be
administered according to the schedule determined by the HBsAg
status of the mother.
HPV vaccine
It has been estimated that in 2012, there were as many as 300
million HPV infections without detectable abnormalities, 10 million
high-grade precancerous lesions [12], and 490 thousand cases of
cervical cancer [13]. Cervical cancer is the third most commonly
diagnosed form of cancer and the fourth leading cause of cancer-
related death among females worldwide. Furthermore, cervical
cancer accounted for 9% (529,800) of new cancer cases and 8%
H.-J. Tsai / Taiwanese Journal of Obstetrics & Gynecology 54 (2015) 112e115114(275,100) of total cancer deaths among females in 2008 [14].
Persistent infection with high-risk HPV is generally accepted as
prerequisite for cervical cancer diagnosis; however, cervical cancer
is a rare complication of HPV infections. This is due to the fact that
such infections tend to be transient and do not give rise to cervical
lesions. It takes an average of 12e15 years before a persistent HPV
infection progresses through consecutive premalignant stages (i.e.,
squamous intraepithelial lesions) and becomes an overt cervical
carcinoma.
HPV and cytomegalovirus (CMV) are ubiquitous, and HPV and
CMV infection are very common. Quadrivalent HPV vaccine (Gar-
dasil, dosing interval 0 months, 2 months, and 6 months) and
Bivalent L1 virus-like particles vaccine (Cervarix, dosing interval
0 months, 1 month, and 6 months) are widely available. Gardasil
provides effective protection against genital warts and vulvar/
vaginal neoplasia associated with the vaccine Types (6, 11, 16, and
18). In other trials, Gardasil protected mid-adult women from
incidental infection of cervical intraepithelial neoplasia (CIN)
caused by the vaccine types and protected men against incidental
infection, genital warts, and anal intraepithelial neoplasia associ-
ated with vaccine types. Cervarix has been shown to protect against
vaccine-targeted anal infections in women [15]. The safety and ef-
ﬁcacy of these two vaccines are not in doubt. For example, in a
combined analysis of four randomized clinical trials (20,583 female
patients aged 16e26 years), the primary endpoint was the devel-
opment of Grade 2 and Grade 3 CIN and adenocarcinoma in situ
(AIS). Among women who tested negative for HPV 16 and HPV 18
infection during the vaccination regimen (n ¼ 17,129, per protocol),
vaccine efﬁcacy was 99% for the primary endpoint 93e100 (95% CI)
[16]. Moreover, HPV vaccines have shown considerable promise as
key components in cervical cancer prevention. Unfortunately, the
high cost of HPV vaccines is a barrier to further implementation.
Despite moral, religious, political, economic, and socio-cultural
controversies, the mandatory HPV vaccination of all middle
school girls can be justiﬁed on scientiﬁc and public health grounds.
The development of vaccines targeting oncogenic types of HPV has
eliminated approximately 70% of all forms of invasive cervical
cancer in women. It is clear that targeted educational initiatives
must be continued to inform healthcare professionals, the media,
patients, and parents about these issues [17].
In the USA, the recommended age for HPV vaccination of fe-
males is 11e12 years and vaccines can be administered to girls as
young as 9 years. Catch-up vaccinations are recommended for fe-
males aged 13e26 years who have not been previously vaccinated
[18]. In Taiwan, the age-speciﬁc seroprevalence of HPV 16 and HPV
18 increases among young adults > 18 years; therefore, the optimal
age for universal HPV vaccination is  15 years [19]. To encourage
adherence to national immunization guidelines, educational ini-
tiatives should be directed toward pediatricians and family physi-
cians. These initiatives should target the modiﬁable predictors of
intention to vaccinate, such as HPV knowledge and attitudes to-
ward vaccination. Furthermore, women up to 45 years of age have
been shown to exhibit strong immune responses to the bivalent
HPV vaccine, which could be expected to reduce the risk of HPV
reinfection and address the second peak of HPV relatedmalignancy
that occurs later in life, generally after 45 years of age. Early data
from randomized trials testing the quadrivalent HPV vaccine in
women older than 25 years also suggest that the vaccine has high
efﬁcacy comparable to younger women [20]. However, when the
vaccine is administered to women up to 45 years of age, the pre-
scribing physician bears the responsibility of off-label use, which
brings with it the possibility of unanticipated risks. Physicians
should therefore be prepared for possible malpractice suits.
Additionally, signiﬁcant cross-protection of the Adjuvant
System 04-adjuvanted HPV 16/HPV 18 vaccine against incidentaland persistent infection has been observed, notably against HPV 45,
the third most prevalent type of HPV associated with cervical
cancer [21]. This protection against HPV 45 could provide an
additional protection against invasive cervical cancer and may also
have a signiﬁcant impact on endocervical adenocarcinoma, a con-
dition that is not effectively prevented by screening and is
becoming increasingly prevalent among young women. Results
from PATRICIA (PApilloma TRIal against Cancer In young Adults)
have demonstrated the cross-protective efﬁcacy of the HPV 16/HPV
18 vaccine against four oncogenic HPVs: HPV 33, HPV 31, HPV 45,
and HPV 51 [22]. In Taiwan, the third most prevalent type of HPV
associated with cervical cancer is HPV 58, followed by HPV 33 and
HPV 52 [23]. These results are on par with those obtained
throughout eastern Asia [24]. It will be interesting to see whether
the HPV vaccine has cross-protection against other types of HPV. In
a follow-up study of 17,622 generally HPV-naive women aged
16e26 years, the vaccine for HPV 6/HPV 11/HPV 16/HPV 18 was
shown to reduce the risk of CIN 2e3/AIS associated with non-
vaccine types of HPV, which are responsible for approximately 20%
of cervical cancer cases [25]. In Phase 3 efﬁcacy studies of sexually
active women aged 16e26 years, vaccination reduced the rate of
HPV 31/HPV 33/HPV 45/HPV 52/HPV 58 infection and also the rate
of CIN 1e3 or AIS [26]. Therefore, these next most common HPV
carcinogenic types should be considered for the development of
second-generation HPV prophylactic vaccines.
Many countries have implemented vaccination programs for
adolescent females and given the indication for use of the vaccine
in males. Both sexes are affected by HPV; therefore, the vaccination
of males against the disease should also be adopted [27]. Despite
the fact that, only limited conclusions can currently be drawn about
the cost-effectiveness of HPV vaccination for males, the vaccination
regime appears more cost-effective when all HPV-related diseases,
and/or lower vaccine prices are considered [28].
An even greater proportion of other HPV-related cancers (i.e.,
noncervical cancers) are caused by HPV 16 and HPV 18 (HPV types
that are targeted by currently available vaccines). For example,
current data indicate that HPV infection is associated with 90e93%
of anal cancers, 12e63% of oropharyngeal cancers, 36e40% of
penile cancers, 40e64% of vaginal cancers, and 40e51% of vulvar
cancers [29]. Therefore, current HPV vaccines show considerable
promise in reducing the burden of both cervical and noncervical
cancers associated with HPV [30]. Moreover, multivalent vaccines
against additional oncogenic HPV strains are currently under
development. Future evaluations should consider the cost-
effectiveness of next generation nonavalent vaccines designed to
protect against up to 90% of all cases of cervical cancer. Further-
more, the effects of vaccination on cervical screening programs are
likely to be country-speciﬁc, depending on the catch-up age range,
coverage of vaccinations, and the age at which screening begins.
Thus, future evaluations should also focus on the effects of dis-
parities in screening and vaccination uptake, the potential effects of
vaccination on screening participation rates, and the effects of
imperfect compliance with screening recommendations [31].
Immunization
Until a human CMV vaccine becomes available, simple hygienic
practices, such as hand washing, can prevent CMV infection both
before and during pregnancy. Preventative behaviors such as hand
washing, not sharing drinking glasses or eating utensils with young
children, and not kissing young children on themouth, appear to be
effective in general [32]. There appears to be a consensus that
inactivated viral vaccines, bacterial vaccines, and toxoids are safe
during pregnancy. Pregnant women are further encouraged to be
vaccinated for inﬂuenza. Womenwho are breastfeeding are eligible
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cines are contraindicated during pregnancy due to a high theoret-
ical risk to the fetus. Moreover, many vaccines require
improvement, because they only cover a portion of the many
pathogenic serotypes that cause disease (rotaviruses, HPV, or
Streptococcus pneumoniae). Developing preventive vaccines against
chronic diseases such as AIDS and hepatitis C will require additional
time. In the future, newmethods of vaccine delivery (i.e., other than
injection) are likely to be used (e.g., mucosal administration) and
new vectors or adjuvants will be added to vaccines to stimulate
speciﬁc responses. Novel vaccines can also be obtained using viral-
like particles (VLPs) of HPV, conjugate polysaccharides (e.g., Neis-
seria meningitidis, S. pneumoniae), and the reassortment of
segmented genomes (e.g., rotavirus, inﬂuenza) [33]. A permanent
advisory committee (Comite technique des vaccinations) in France,
has already established ofﬁcial guidelines regardingwhich vaccines
should be used to treat various conditions, the target population
(i.e., universal or limited to a selected population), and the immu-
nization schedules. After a vaccine is recommended, the Trans-
parency Commission for Transmissible Diseases of the Superior
Public Health Authority (Haute Autorite de Sante) and the economic
committee on drugs, usually make decisions regarding reim-
bursement by the public health care fund. These guidelines become
part of the immunization schedule, which is updated annually and
published in the Ofﬁcial Bulletin of theMinister of Health and in the
Bulletin epidemiologique hebdomadaire [34].
In conclusion, both HBV and HPV vaccines are considered major
successes in the chemoprevention of cancer.Conﬂicts of interest
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